

Supplementary Information

Direct access to isoindolines through tandem Rh(III)-catalyzed alkenylation and cyclization of *N*-benzyltriflamides

Neeraj Kumar Mishra, Jihye Park, Satyasheel Sharma, Sangil Han, Mirim Kim, Youngmi Shin, Jinbong Jang, Jong Hwan Kwak, Young Hoon Jung, and In Su Kim*

School of Pharmacy, Sungkyunkwan University, Suwon 440-746, Republic of Korea

* Corresponding author. Tel.: +82-31-290-7788; fax: +82-31-292-8800; e-mail: insukim@skku.edu

List of the Contents

General methods -----	S2
General procedure for the synthesis of <i>N</i> -benzyltriflamides (1a–p) -----	S3
Typical procedure for the synthesis of isoindolines -----	S3
Optimization table -----	S4
Characterization data for products (3a–p and 4b–j) -----	S5–S17
Chemoselectivity between triflamine 1a and α,β-unsaturated ketones 2i and 2j depending on solvents -----	S18
Competition experiments and characterization data (5b, 6b and 6c) -----	S19–S20
General procedure for the deprotection of triflamine group -----	S21
General procedure of mechanistic studies and ¹ H NMR data -----	S22–S23
¹ H NMR and ¹³ C NMR copies of all products -----	S24–S55

General methods

Commercially available reagents were used without additional purification, unless otherwise stated. Sealed tubes ($13 \times 100 \text{ mm}^2$) were purchased from Fischer Scientific and dried in oven for overnight and cooled at room temperature prior to use. Thin layer chromatography was carried out using plates coated with Kieselgel 60F₂₅₄ (Merck). For flash column chromatography, E. Merck Kieselgel 60 (230–400 mesh) was used. Nuclear magnetic resonance spectra (¹H and ¹³C NMR) were recorded on a Bruker Unity 400 and 700 MHz spectrometer for CDCl₃ solution and chemical shifts are reported as parts per million (ppm). Resonance patterns are reported with the notations s (singlet), d (doublet), t (triplet), q (quartet), and m (multiplet). In addition, the notation br is used to indicate a broad signal. Coupling constants (*J*) are reported in hertz (Hz). IR spectra were recorded on a Varian 2000 Infrared spectrophotometer and are reported as cm⁻¹. High-resolution mass spectra (HRMS) were recorded on a JEOL JMS-600 spectrometer.

General procedure for the synthesis of *N*-benzyltriflamides (**1a–p**)


N-Benzyltriflamides were prepared from the corresponding benzylamines and trifluoromethanesulfonic anhydride as described in previous literature.¹

Typical procedure for the synthesis of isoindolines (**3a–p**, **4b–j**, **5b**, **6b** and **6c**)

To an oven-dried sealed tube charged with *N*-(2-methoxybenzyl)triflameide (**1a**) (80.8 mg, 0.3 mmol, 100 mol %), [RhCp^{*}Cl₂]₂ (4.6 mg, 0.0075 mmol, 2.5 mol %), and Cu(OAc)₂.H₂O (120 mg, 0.6 mmol, 200 mol %) in DMF:AcOH (3:1, 1 mL) was added *n*-butyl acrylate (**2a**) (64 μL, 0.45 mmol, 150 mol %). The reaction mixture was allowed to stir for 24 h at 110 °C. The reaction mixture was diluted with EtOAc (10 mL) and washed with water. The aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organic layer was dried over Mg₂SO₄ and concentrated in vacuo. The residue was purified by flash column chromatography (*n*-hexanes/EtOAc = 25:1) to afford isoindoline **3a** (107.9 mg) in 91% yield.

1) Wang, X.; Mei, T.-S.; Yu, J.-Q. *J. Am. Chem. Soc.*, **2009**, *131*, 7520.


Optimization table



entry	catalyst (mol %)	Oxidant (mol %)	solvent	yield (%)	
				3a	3aa
1	Pd(OAc) ₂ (10)	Cu(OAc) ₂ (200)	DCE	trace	27
2	Pd(OAc) ₂ (10)	AgOAc (200)	DCE	0	0
3	Pd(OAc) ₂ (10)	Cu(OAc) ₂ (200)	DMF	17	16
4	[RhCp*Cl ₂] ₂ (2.5)	Cu(OAc) ₂ (200)	DMF	53	12
5	[RhCp*Cl ₂] ₂ (2.5)	Cu(OAc) ₂ .H ₂ O (200)	DMF	62	10
6	[RhCp*Cl ₂] ₂ (2.5)	Cu(OAc) ₂ .H ₂ O (200)	THF	31	39
7	[RhCp*Cl ₂] ₂ (2.5)	Cu(OAc) ₂ .H ₂ O (200)	DCE	33	40
8	[RhCp*Cl ₂] ₂ (2.5)	Cu(OAc) ₂ .H ₂ O (200)	MeCN	61	8
9	[RhCp*Cl ₂] ₂ (2.5)	Cu(OAc) ₂ .H ₂ O (200)	DMF/AcOH (3:1)	91	trace
10	[RhCp*Cl ₂] ₂ (2.5)	Cu(OAc) ₂ .H ₂ O (200)	MeCN/AcOH (3:1)	7	0
11	[RhCp*Cl ₂] ₂ (2.5) AgSbF ₆ (10)	Cu(OAc) ₂ .H ₂ O (200)	DMF/AcOH (3:1)	82	trace
12	[RhCp*Cl ₂] ₂ (2.5)	Cu(OAc) ₂ .H ₂ O (100)	DMF/AcOH (3:1)	69	4


Characterization data for products (3a–p and 4b–j)

Butyl 2-(4-methoxy-2-(trifluoromethylsulfonyl)isoindolin-1-yl)acetate (3a)




¹H NMR (700 MHz, CDCl₃) δ 7.27 (t, *J* = 7.9 Hz, 1H), 6.80 (d, *J* = 7.7 Hz, 1H), 6.78 (d, *J* = 8.2 Hz, 1H), 5.55 (br s, 1H), 4.87 (d, *J* = 13.7 Hz, 1H), 4.73 (d, *J* = 13.7 Hz, 1H), 4.05–3.99 (m, 2H), 3.82 (s, 3H), 3.03 (dd, *J* = 16.3, 3.5 Hz, 1H), 2.92 (dd, *J* = 16.3, 7.2 Hz, 1H), 1.52–1.50 (m, 2H), 1.29–1.25 (m, 2H), 0.87 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 169.5, 154.4, 139.6, 130.2, 122.9, 120.1 (q, *J*_{C–F} = 322.0 Hz), 114.3, 109.7, 64.6, 63.7, 55.2, 52.8, 41.2, 30.4, 18.9, 13.5; IR (KBr) ν 2961, 1733, 1602, 1489, 1388, 1271, 1180, 1062, 1000, 895, 774 cm⁻¹; HRMS (EI) calcd for C₁₆H₂₀F₃NO₅S [M]⁺ 395.1014, found 395.1017.

(E)-Butyl 3-(3-methoxy-2-(trifluoromethylsulfonamido)methyl)phenylacrylate (3aa)




¹H NMR (700 MHz, CDCl₃) δ 8.01 (d, *J* = 15.6 Hz, 1H), 7.32 (d, *J* = 8.0 Hz, 1H), 7.14 (d, *J* = 7.8 Hz, 1H), 6.92 (d, *J* = 7.8 Hz, 1H), 6.31 (d, *J* = 15.6 Hz, 1H), 5.62 (br s, 1H), 4.54 (d, *J* = 5.8 Hz, 2H), 4.17 (t, *J* = 6.6 Hz, 2H), 3.87 (s, 3H), 1.67–1.65 (m, 2H), 1.43–1.41 (m, 2H), 0.93 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 166.3, 158.0, 140.3, 135.0, 130.0, 122.7, 122.6, 119.9 (q, *J*_{C–F} = 320.6 Hz), 119.4, 111.5, 64.6, 55.7, 39.6, 30.6, 19.1, 13.6; IR (KBr) ν 2961, 1695, 1578, 1444, 1372, 1264, 1179, 1142, 1048, 982, 865, 733 cm⁻¹; HRMS (EI) calcd for C₁₆H₂₀F₃NO₅S [M]⁺ 395.1014, found 395.1015.

Butyl 2-(4-methyl-2-(trifluoromethylsulfonyl)isoindolin-1-yl)acetate (3b)




¹H NMR (700 MHz, CDCl₃) δ 7.22 (t, *J* = 7.5 Hz, 1H), 7.11 (d, *J* = 7.4 Hz, 1H), 7.05 (d, *J* = 7.7 Hz, 1H), 5.58 (br s, 1H), 4.85 (d, *J* = 13.3 Hz, 1H), 4.76 (d, *J* = 13.3 Hz, 1H), 4.04–3.98 (m, 2H), 3.04 (d, *J* = 16.4 Hz, 1H), 2.94 (dd, *J* = 16.5, 7.0 Hz, 1H), 2.24 (s, 3H), 1.51–1.49 (m, 2H), 1.28–1.24 (m, 2H), 0.87 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 169.4, 137.7, 133.8, 132.4, 129.4, 128.6, 120.1 (q, *J*_{C-F} = 325.0 Hz), 64.5, 63.6, 53.9, 41.1, 30.3, 18.9, 18.4, 13.5; IR (KBr) ν 2962, 1732, 1467, 1387, 1225, 1180, 1157, 1066, 776 cm⁻¹; HRMS (EI) calcd for C₁₆H₂₀F₃NO₄S [M]⁺ 379.1065, found 379.1061.

Butyl 2-(4,6-dimethoxy-2-(trifluoromethylsulfonyl)isoindolin-1-yl)acetate (3c)




¹H NMR (700 MHz, CDCl₃) δ 6.35 (d, *J* = 1.9 Hz, 1H), 6.32 (d, *J* = 1.6 Hz, 1H), 5.49 (br s, 1H), 4.78 (d, *J* = 13.0 Hz, 1H), 4.65 (d, *J* = 13.0 Hz, 1H), 4.06–4.01 (m, 2H), 3.78 (s, 3H), 3.75 (s, 3H), 3.03 (dd, *J* = 16.3, 3.6 Hz, 1H), 2.88 (dd, *J* = 16.3, 7.4 Hz, 1H), 1.54–1.51 (m, 2H), 1.30–1.26 (m, 2H), 0.87 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 169.6, 162.0, 155.1, 140.1, 120.2 (q, *J*_{C-F} = 323.0 Hz), 115.3, 98.3, 98.2, 64.9, 63.7, 55.5, 55.3, 52.4, 41.3, 30.4, 18.9, 13.5; IR (KBr) ν 2962, 1732, 1610, 1502, 1465, 1388, 1342, 1225, 1200, 1149, 1069, 1001, 935, 836, 735 cm⁻¹; HRMS (EI) calcd for C₁₇H₂₂F₃NO₆S [M]⁺ 425.1120, found 425.1118.

Butyl 2-(4-fluoro-2-(trifluoromethylsulfonyl)isoindolin-1-yl)acetate (3d)




¹H NMR (700 MHz, CDCl₃) δ 7.31–7.30 (m, 1H), 7.04–7.01 (m, 2H), 5.57 (br s, 1H), 4.97 (d, *J* = 13.7 Hz, 1H), 4.85 (d, *J* = 13.7 Hz, 1H), 4.05–3.99 (m, 2H), 3.05–2.96 (m, 2H), 1.53–1.49 (m, 2H), 1.28–1.25 (m, 2H), 0.87 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 169.2, 157.2 (d, *J*_{C-F} = 249.6 Hz), 141.2, 130.7 (d, *J*_{C-F} = 6.4 Hz), 122.1 (d, *J*_{C-F} = 18.3 Hz), 120.0 (q, *J*_{C-F} = 326.9 Hz), 118.2, 115.2 (d, *J*_{C-F} = 19.2 Hz), 64.7, 63.4, 51.8, 40.7, 30.4, 18.9, 13.5; IR (KBr) ν 2963, 1733, 1631, 1599, 1480, 1390, 1226, 1184, 1157, 1067, 919, 781 cm⁻¹; HRMS (EI) calcd for C₁₅H₁₇F₄NO₄S [M]⁺ 383.0814, found 383.0809.

Butyl 2-(4-chloro-2-(trifluoromethylsulfonyl)isoindolin-1-yl)acetate (3e)



¹H NMR (700 MHz, CDCl₃) δ 7.28 (m, 2H), 7.14 (d, *J* = 7.3 Hz, 1H), 5.60 (br s, 1H), 4.93 (d, *J* = 14.1 Hz, 1H), 4.81 (d, *J* = 14.1 Hz, 1H), 4.04–3.98 (m, 2H), 3.03 (d, *J* = 16.8 Hz, 1H), 2.98 (dd, *J* = 16.8, 7.0 Hz, 1H), 1.51–1.49 (m, 2H), 1.28–1.24 (m, 2H), 0.87 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 169.2, 139.9, 133.8, 130.1, 128.8, 128.7, 120.8, 120.0 (q, *J*_{C-F} = 322.0 Hz), 64.7, 63.9, 54.1, 40.7, 30.3, 18.9, 13.5; IR (KBr) ν 2962, 1733, 1586, 1458, 1389, 1227, 1181, 1148, 1065, 995, 861, 777 cm⁻¹; HRMS (EI) calcd for C₁₅H₁₇ClF₃NO₄S [M]⁺ 399.0519, found 399.0518.


Butyl 2-(5-methyl-2-(trifluoromethylsulfonyl)isoindolin-1-yl)acetate (3f)



¹H NMR (700 MHz, CDCl₃) δ 7.11 (s, 2H), 7.04 (s, 1H), 5.52 (br s, 1H), 4.86 (d, *J* = 13.3 Hz, 1H), 4.80 (d, *J* = 13.3 Hz, 1H), 4.03–4.00 (m, 2H), 3.01 (dd, *J* = 16.4, 3.5 Hz, 1H), 2.92 (dd, *J* = 16.3, 7.1 Hz, 1H), 2.34 (s, 3H), 1.52–1.50 (m, 2H), 1.29–1.25 (m, 2H), 0.87 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 169.5, 138.7, 135.1, 134.9, 129.2, 122.8, 122.2, 120.1 (q, *J*_{C-F} = 323.8 Hz), 64.6, 63.1, 54.3, 41.1, 30.4, 21.2, 18.9, 13.5; IR (KBr) ν 2961, 1732, 1462,


1388, 1225, 1181, 1157, 1064, 971, 818, 776 cm^{-1} ; HRMS (EI) calcd for $\text{C}_{16}\text{H}_{20}\text{F}_3\text{NO}_4\text{S} [\text{M}]^+$ 379.1065, found 379.1065.

Butyl 2-(5-(trifluoromethyl)-2-(trifluoromethylsulfonyl)isoindolin-1-yl)acetate (3g)




^1H NMR (700 MHz, CDCl_3) δ 7.59 (d, $J = 8.1$ Hz, 1H), 7.51 (s, 1H), 7.39 (d, $J = 8.0$ Hz, 1H), 5.59 (br s, 1H), 4.96 (d, $J = 13.7$ Hz, 1H), 4.89 (d, $J = 13.7$ Hz, 1H), 4.04–3.99 (m, 2H), 3.08–2.99 (m, 2H), 1.52–1.48 (m, 2H), 1.28–1.23 (m, 2H), 0.87 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (175 MHz, CDCl_3) δ 169.2, 141.9, 136.0, 131.4 (q, $J_{\text{C}-\text{F}} = 32.5$ Hz), 125.6 (q, $J_{\text{C}-\text{F}} = 3.2$ Hz), 123.7 (q, $J_{\text{C}-\text{F}} = 272.3$ Hz), 123.2, 120.0 (q, $J_{\text{C}-\text{F}} = 331.3$ Hz), 119.7 (q, $J_{\text{C}-\text{F}} = 3.8$ Hz), 64.9, 62.9, 54.2, 40.5, 30.4, 18.9, 13.5; IR (KBr) ν 2964, 1732, 1441, 1390, 1326, 1227, 1159, 1125, 1059, 893, 778 cm^{-1} ; HRMS (EI) calcd for $\text{C}_{16}\text{H}_{17}\text{F}_6\text{NO}_4\text{S} [\text{M}]^+$ 433.0782, found 433.0784.

Butyl 2-(5-chloro-2-(trifluoromethylsulfonyl)isoindolin-1-yl)acetate (3h)




^1H NMR (700 MHz, CDCl_3) δ 7.28 (dd, $J = 8.1, 1.8$ Hz, 1H), 7.23 (s, 1H), 7.18 (d, $J = 8.2$ Hz, 1H), 5.51 (br s, 1H), 4.87 (d, $J = 13.7$ Hz, 1H), 4.81 (d, $J = 13.7$ Hz, 1H), 4.03–3.99 (m, 2H), 3.02 (dd, $J = 16.7, 3.0$ Hz, 1H), 2.94 (dd, $J = 16.7, 7.0$ Hz, 1H), 1.53–1.49 (m, 2H), 1.29–1.25 (m, 2H), 0.87 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (175 MHz, CDCl_3) δ 169.3, 136.9, 136.5, 134.8, 128.7, 123.8, 122.7, 120.0 (q, $J_{\text{C}-\text{F}} = 321.3$ Hz), 64.8, 62.8, 54.1, 40.7, 30.4, 18.9, 13.5; IR (KBr) ν 2962, 1731, 1388, 1226, 1183, 1156, 1062, 998, 885, 776 cm^{-1} ; HRMS (EI) calcd for $\text{C}_{15}\text{H}_{17}\text{ClF}_3\text{NO}_4\text{S} [\text{M}]^+$ 399.0519, found 399.0494.

(E)-Butyl 3-(1-(2-butoxy-2-oxoethyl)-2-(trifluoromethylsulfonyl)isoindolin-4-yl)acrylate (3i)




¹H NMR (700 MHz, CDCl₃) δ 7.54–7.51 (m, 2H), 7.35 (t, *J* = 7.7 Hz, 1H), 7.24 (d, *J* = 7.7 Hz, 1H), 6.31 (d, *J* = 16.0 Hz, 1H), 5.56 (br s, 1H), 5.03 (d, *J* = 13.6 Hz, 1H), 4.94 (d, *J* = 13.6 Hz, 1H), 4.01–3.96 (m, 2H), 3.02–2.96 (m, 2H), 1.69–1.64 (m, 2H), 1.49–1.46 (m, 2H), 1.42–1.39 (m, 2H), 1.25–1.22 (m, 2H), 0.93 (t, *J* = 7.3 Hz, 3H), 0.84 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 169.3, 166.3, 139.9, 139.0, 134.5, 129.6, 129.1, 127.3, 123.8, 121.2, 120.0 (q, *J*_{C-F} = 330.6 Hz), 64.73, 64.71, 63.0, 54.1, 40.6, 30.6, 30.3, 19.1, 18.9, 13.6, 13.5; IR (KBr) ν 2961, 1731, 1712, 1640, 1593, 1456, 1389, 1226, 1178, 1160, 1064, 979, 866, 787 cm⁻¹; HRMS (EI) calcd for C₂₂H₂₈F₃NO₆S [M]⁺ 491.1589, found 491.1591.

(E)-Butyl 3-(1-(2-butoxy-2-oxoethyl)-6-methoxy-2-(trifluoromethylsulfonyl)isoindolin-4-yl)acrylate (3j)




¹H NMR (700 MHz, CDCl₃) δ 7.46 (d, *J* = 16.0 Hz, 1H), 7.01 (s, 1H), 6.79 (s, 1H), 6.28 (d, *J* = 16.0 Hz, 1H), 5.51 (br s, 1H), 4.95 (d, *J* = 13.0 Hz, 1H), 4.87 (d, *J* = 13.0 Hz, 1H), 4.20–4.18 (m, 2H), 4.05–3.99 (m, 2H), 3.79 (s, 3H), 3.02–2.93 (m, 2H), 1.69–1.62 (m, 2H), 1.52–1.49 (m, 2H), 1.42–1.39 (m, 2H), 1.28–1.22 (m, 2H), 0.94 (t, *J* = 7.4 Hz, 3H), 0.86 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 169.4, 166.3, 160.4, 140.1, 130.3, 129.3, 121.3, 114.3, 112.8, 109.8, 64.8, 64.7, 62.9, 55.6, 53.6, 40.9, 30.6, 30.4, 19.1, 18.9, 13.6, 13.5; IR (KBr) ν 2961, 1728, 1715, 1641, 1466, 1389, 1271, 1226, 1175, 1067, 1042, 975, 850, 735 cm⁻¹; HRMS (EI) calcd for C₂₃H₃₀F₃NO₇S [M]⁺ 521.1695, found 521.1694.

(E)- Butyl 3-(1-(2-butoxy-2-oxoethyl)-6-methyl-2-(trifluoromethylsulfonyl)isoindolin-4-yl)acrylate (3k)




^1H NMR (700 MHz, CDCl_3) δ 7.50 (d, $J = 16.0$ Hz, 1H), 7.32 (s, 1H), 7.05 (s, 1H), 6.29 (d, $J = 16.0$ Hz, 1H), 5.51 (br s, 1H), 4.97 (d, $J = 13.4$ Hz, 1H), 4.89 (d, $J = 13.4$ Hz, 1H), 4.20–4.17 (m, 2H), 4.04–3.96 (m, 2H), 3.02–2.94 (m, 2H), 2.34 (s, 3H), 1.68–1.64 (m, 2H), 1.50–1.47 (m, 2H), 1.42–1.39 (m, 2H), 1.26–1.23 (m, 2H), 0.93 (t, $J = 7.3$ Hz, 3H), 0.85 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (175 MHz, CDCl_3) δ 169.3, 166.4, 140.2, 139.2, 131.7, 129.2, 128.2, 124.5, 120.8, 120.0 (q, $J_{\text{C}-\text{F}} = 323.7$ Hz), 64.6, 64.5, 62.9, 53.9, 40.8, 30.6, 30.4, 21.1, 19.1, 18.9, 13.6, 13.5; IR (KBr) ν 2961, 1728, 1713, 1640, 1463, 1389, 1269, 1226, 1175, 1067, 975, 857, 735 cm^{-1} ; HRMS (EI) calcd for $\text{C}_{23}\text{H}_{30}\text{F}_3\text{NO}_6\text{S} [\text{M}]^+$ 505.1746, found 505.1736.

(E)- Butyl 3-(1-(2-butoxy-2-oxoethyl)-6-chloro-2-(trifluoromethylsulfonyl)isoindolin-4-yl)acrylate (3l)




^1H NMR (700 MHz, CDCl_3) δ 7.49 (s, 1H), 7.44 (d, $J = 16.0$ Hz, 1H), 7.24 (s, 1H), 6.33 (d, $J = 16.0$ Hz, 1H), 5.51 (br s, 1H), 4.97 (d, $J = 13.7$ Hz, 1H), 4.89 (d, $J = 13.7$ Hz, 1H), 4.21–4.18 (m, 2H), 4.05–3.97 (m, 2H), 3.00–2.96 (m, 2H), 1.68–1.64 (m, 2H), 1.51–1.49 (m, 2H), 1.41–1.38 (m, 2H), 1.28–1.24 (m, 2H), 0.93 (t, $J = 7.3$ Hz, 3H), 0.86 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (175 MHz, CDCl_3) δ 169.1, 165.9, 140.8, 138.4, 135.1, 133.1, 130.9, 127.1, 123.9, 122.5, 120.0 (q, $J_{\text{C}-\text{F}} = 332.7$ Hz), 64.9, 64.8, 62.6, 53.7, 40.2, 30.6, 30.4, 19.1, 18.9, 13.6, 13.5; IR (KBr) ν 2961, 2046, 1731, 1713, 1643, 1592, 1459, 1389, 1226, 1177, 1160, 1067, 974, 862, 737 cm^{-1} ; HRMS (EI) calcd for $\text{C}_{22}\text{H}_{27}\text{ClF}_3\text{NO}_6\text{S} [\text{M}]^+$ 525.1200, found 525.1183.

(E)-Methyl 3-(2-butoxy-2-oxoethyl)-7-(3-butoxy-3-oxoprop-1-enyl)-2-(trifluoromethylsulfonyl)isoindoline-5-carboxylate (3m)




¹H NMR (700 MHz, CDCl₃) δ 8.22 (s, 1H), 7.88 (s, 1H), 7.53 (d, *J* = 15.9 Hz, 1H), 6.44 (d, *J* = 15.9 Hz, 1H), 5.56 (br s, 1H), 5.06 (d, *J* = 14.2 Hz, 1H), 5.01 (d, *J* = 14.2 Hz, 1H), 4.21 (t, *J* = 6.6 Hz, 2H), 4.03–3.99 (m, 2H), 3.92 (s, 3H), 3.09–3.02 (m, 2H), 1.70–1.66 (m, 2H), 1.50–1.39 (m, 4H), 1.27–1.22 (m, 2H), 0.95 (t, *J* = 7.4 Hz, 3H), 0.84 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 169.0, 166.0, 165.6, 138.7, 131.5, 129.8, 128.5, 124.4, 122.4, 119.9 (q, *J*_{C-F} = 315.9 Hz), 64.9, 64.8, 62.9, 54.3, 52.5, 40.0, 30.6, 30.3, 19.1, 18.9, 13.6, 13.5; IR (KBr) ν 2960, 1719, 1644, 1596, 1437, 1390, 1276, 1225, 1179, 1069, 976, 734 cm⁻¹; HRMS (EI) calcd for C₂₄H₃₀F₃NO₈S [M]⁺ 549.1644, found 549.1649.

Butyl 2-(3-methyl-2-(trifluoromethylsulfonyl)isoindolin-1-yl)acetate (3n)




¹H NMR (700 MHz, CDCl₃) δ 7.35–7.33 (m, 1H), 7.31–7.27 (m, 2H), 7.18 (d, *J* = 7.4 Hz, 1H), 5.56 (br s, 1H), 5.20 (br s, 1H), 4.11 (t, *J* = 6.7 Hz, 2H), 3.17 (d, *J* = 15.1 Hz, 1H), 2.74 (dd, *J* = 15.9, 9.0 Hz, 1H), 1.62 (d, *J* = 6.5 Hz, 3H), 1.59–1.57 (m, 2H), 1.35–1.32 (m, 2H), 0.91 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 169.7, 139.9, 137.5, 128.2, 128.5, 123.0, 122.2, 64.8, 63.1, 62.9, 44.3, 30.4, 25.2, 19.0, 13.6; IR (KBr) ν 2963, 1731, 1461, 1391, 1302, 1225, 1181, 1151, 1061, 980, 751 cm⁻¹; HRMS (EI) calcd for C₁₆H₂₀F₃NO₄S [M]⁺ 379.1065, found 379.1057.

Butyl 2-(3,3-dimethyl-2-(trifluoromethylsulfonyl)isoindolin-1-yl)acetate (3o)




¹H NMR (700 MHz, CDCl₃) δ 7.34 (t, *J* = 7.8 Hz, 1H), 7.29 (t, *J* = 7.8 Hz, 1H), 7.24 (br s, 1H), 7.12 (d, *J* = 7.7 Hz, 1H), 5.54 (br s, 1H), 4.11 (t, *J* = 6.5 Hz, 2H), 3.48 (d, *J* = 15.1 Hz, 1H), 2.70–2.69 (m, 2H), 1.78 (s, 3 H), 1.74 (s, 3 H), 1.59–1.57 (m, 2H), 1.35–1.32 (m, 2H), 0.90 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 170.2, 144.5, 140.7, 128.9, 128.5, 122.6, 121.4, 64.7, 62.9, 53.4, 44.3, 32.7, 30.6, 30.5, 27.4, 19.0, 13.6; IR (KBr) ν 2961, 1730, 1461, 1379, 1221, 1181, 1150, 1040, 941, 737 cm⁻¹; HRMS (EI) calcd for C₁₇H₂₂F₃NO₄S [M]⁺ 393.1222, found 393.1216.

(E)-Butyl 3-((trifluoromethylsulfonamido)methyl)thiophen-3-yl)acrylate (3p)



¹H NMR (700 MHz, CDCl₃) δ 7.62 (d, *J* = 15.6 Hz, 1H), 7.30 (d, *J* = 5.3 Hz, 1H), 7.22 (d, *J* = 5.3 Hz, 1H), 6.27 (d, *J* = 15.6 Hz, 1H), 5.31 (br s, 1H), 4.70 (d, *J* = 5.7 Hz, 2H), 4.17 (t, *J* = 6.6 Hz, 2H), 1.68–1.64 (m, 2H), 1.42–1.39 (m, 2H), 0.94 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 167.0, 138.1, 135.3, 134.0, 126.5, 125.8, 120.0, 64.7, 40.3, 30.6, 19.1, 13.7; IR (KBr) ν 2922, 1689, 1630, 1453, 1376, 1301, 1229, 1183, 1143, 1054, 973, 861, 752 cm⁻¹; HRMS (EI) Calcd for C₁₃H₁₆F₃NO₄S₂ [M]⁺ 371.0473, found 371.0478.


Methyl 2-(4-methoxy-2-(trifluoromethylsulfonyl)isoindolin-1-yl)acetate (4b)



¹H NMR (700 MHz, CDCl₃) δ 7.28 (t, *J* = 7.9 Hz, 1H), 6.80 (d, *J* = 8.0 Hz, 2H), 5.56 (br s, 1H), 4.87 (d, *J* = 13.7 Hz, 1H), 4.74 (d, *J* = 13.7 Hz, 1H), 3.82 (s, 3H), 3.63 (s, 3H), 3.05 (dd, *J* = 16.3, 3.7 Hz, 1H), 2.90 (dd, *J* = 16.3, 7.4 Hz, 1H); ¹³C NMR (175 MHz, CDCl₃) δ 169.8, 154.4, 139.6, 130.2, 123.0, 120.1 (q, J_{C-F} = 323.2 Hz), 114.2, 109.7, 63.6, 55.2, 52.7, 51.7, 41.0;


IR (KBr) ν 2955, 1738, 1601, 1489, 1388, 1271, 1224, 1177, 1155, 1061, 999, 892, 775 cm^{-1} ; HRMS (EI) calcd for $\text{C}_{13}\text{H}_{14}\text{F}_3\text{NO}_5\text{S} [\text{M}]^+$ 353.0545, found 353.0540.

Ethyl 2-(4-methoxy-2-(trifluoromethylsulfonyl)isoindolin-1-yl)acetate (4c)




^1H NMR (700 MHz, CDCl_3) δ 7.28 (t, $J = 7.9$ Hz, 1H), 6.81–6.78 (m, 2H), 5.56 (br s, 1H), 4.87 (d, $J = 13.7$ Hz, 1H), 4.73 (d, $J = 13.7$ Hz, 1H), 4.09–4.07 (m, 2H), 3.82 (s, 3H), 3.03 (dd, $J = 16.3, 3.4$ Hz, 1H), 2.90 (dd, $J = 16.3, 7.2$ Hz, 1H), 1.17 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (175 MHz, CDCl_3) δ 169.4, 154.4, 139.6, 130.2, 123.1, 120.0 (q, $J_{\text{C}-\text{F}} = 321.0$ Hz), 114.3, 109.7, 63.7, 60.7, 55.3, 52.8, 41.2, 13.9; IR (KBr) ν 2941, 2056, 1732, 1602, 1489, 1387, 1271, 1225, 1179, 1155, 1062, 872, 774 cm^{-1} ; HRMS (EI) calcd for $\text{C}_{14}\text{H}_{16}\text{F}_3\text{NO}_5\text{S} [\text{M}]^+$ 367.0701, found 367.0699.

tert-Butyl 2-(4-methoxy-2-(trifluoromethylsulfonyl)isoindolin-1-yl)acetate (4d)




^1H NMR (700 MHz, CDCl_3) δ 7.28 (t, $J = 7.9$ Hz, 1H), 6.84 (d, $J = 7.7$ Hz, 1H), 6.78 (d, $J = 8.1$ Hz, 1H), 5.53 (br s, 1H), 4.86 (d, $J = 13.7$ Hz, 1H), 4.71 (d, $J = 13.7$ Hz, 1H), 3.82 (s, 3H), 2.96 (dd, $J = 16.1, 3.3$ Hz, 1H), 2.84 (dd, $J = 16.1, 7.2$ Hz, 1H), 1.33 (s, 9H); ^{13}C NMR (175 MHz, CDCl_3) δ 168.6, 154.4, 139.9, 130.1, 123.0, 120.2 (q, $J_{\text{C}-\text{F}} = 326.1$ Hz), 114.5, 109.6, 81.2, 64.0, 55.3, 52.8, 42.4, 27.8; IR (KBr) ν 2978, 2057, 1726, 1602, 1489, 1389, 1367, 1271, 1225, 1182, 1145, 1061, 1000, 952, 898, 776 cm^{-1} ; HRMS (EI) calcd for $\text{C}_{16}\text{H}_{20}\text{F}_3\text{NO}_5\text{S} [\text{M}]^+$ 395.1014, found 395.1019.

Benzyl 2-(4-methoxy-2-(trifluoromethylsulfonyl)isoindolin-1-yl)acetate (4e)




¹H NMR (700 MHz, CDCl₃) δ 7.33–7.32 (m, 3H), 7.26–7.25 (m, 3H), 6.78 (d, *J* = 8.1 Hz, 1H), 6.74 (d, *J* = 7.7 Hz, 1H), 5.58 (br s, 1H), 5.09 (d, *J* = 12.1 Hz, 1H), 5.04 (d, *J* = 12.1 Hz, 1H), 4.85 (d, *J* = 13.7 Hz, 1H), 4.67 (d, *J* = 13.7 Hz, 1H), 3.83 (s, 3H), 3.10 (dd, *J* = 16.3, 3.7 Hz, 1H), 2.99 (dd, *J* = 16.3, 7.0 Hz, 1H); ¹³C NMR (175 MHz, CDCl₃) δ 169.2, 154.4, 135.2, 130.2, 129.7, 128.5, 128.3, 120.9, 114.3, 110.4, 109.7, 66.6, 63.7, 55.2, 52.8, 41.2; IR (KBr) ν 2941, 2159, 1735, 1602, 1489, 1385, 1270, 1225, 1183, 1156, 1063, 734 cm⁻¹; HRMS (EI) calcd for C₁₉H₁₈F₃NO₅S [M]⁺ 429.0858, found 429.0848.

Phenyl 2-(4-methoxy-2-(trifluoromethylsulfonyl)isoindolin-1-yl)acetate (4f)



¹H NMR (700 MHz, CDCl₃) δ 7.34–7.32 (m, 3H), 7.20 (t, *J* = 7.4 Hz, 1H), 6.94–6.89 (m, 3H), 6.82 (d, *J* = 8.1 Hz, 1H), 5.66 (br s, 1H), 4.91 (d, *J* = 13.6 Hz, 1H), 4.79 (d, *J* = 13.6 Hz, 1H), 3.82 (s, 3H), 3.30–3.23 (m, 2H); ¹³C NMR (175 MHz, CDCl₃) δ 168.0, 154.5, 150.1, 139.1, 130.3, 129.4, 126.0, 123.3, 121.3, 114.3, 109.9, 63.3, 55.3, 53.0, 41.0; IR (KBr) ν 2942, 2159, 1757, 1600, 1491, 1388, 1269, 1226, 1187, 1142, 1063, 734 cm⁻¹; HRMS (EI) calcd for C₁₈H₁₆F₃NO₅S [M]⁺ 415.0701, found 415.0698.


2-(4-Methoxy-2-(trifluoromethylsulfonyl)isoindolin-1-yl)-N,N-dimethylacetamide (4g)



¹H NMR (700 MHz, CDCl₃) δ 7.24 (t, *J* = 7.9 Hz, 1H), 6.98 (d, *J* = 7.7 Hz, 1H), 6.77 (d, *J* = 8.1 Hz, 1H), 5.72 (br s, 1H), 4.86 (d, *J* = 13.9 Hz, 1H), 4.73 (d, *J* = 13.9 Hz, 1H), 3.81 (s, 3H),


3.13 (d, $J = 15.9$ Hz, 1H), 2.92 (s, 3H), 2.91 (s, 3H), 2.80 (dd, $J = 16.0, 9.1$ Hz, 1H); ^{13}C NMR (175 MHz, CDCl_3) δ 168.7, 154.2, 140.9, 130.0, 123.0, 120.2 (q, $J_{\text{C}-\text{F}} = 323.7$ Hz), 115.5, 109.4, 64.3, 55.2, 52.5, 40.9, 37.1, 35.3; IR (KBr) ν 2939, 1995, 1643, 1599, 1488, 1385, 1270, 1224, 1180, 1150, 1059, 998, 896, 778 cm^{-1} ; HRMS (EI) calcd for $\text{C}_{14}\text{H}_{17}\text{F}_3\text{N}_2\text{O}_4\text{S} [\text{M}]^+$ 366.0861, found 366.0845.

2-(4-Methoxy-2-(trifluoromethylsulfonyl)isoindolin-1-yl)acetonitrile (4h)




^1H NMR (700 MHz, CDCl_3) δ 7.38 (t, $J = 8.0$ Hz, 1H), 6.91 (d, $J = 7.7$ Hz, 1H), 6.87 (d, $J = 8.1$ Hz, 1H), 5.42 (br s, 1H), 4.90 (d, $J = 13.7$ Hz, 1H), 4.84 (d, $J = 13.7$ Hz, 1H), 3.84 (s, 3H), 3.11 (dd, $J = 16.9, 6.0$ Hz, 1H), 2.95 (d, $J = 16.9$ Hz, 1H); ^{13}C NMR (175 MHz, CDCl_3) δ 154.7, 136.9, 130.8, 123.1, 120.0 (q, $J_{\text{C}-\text{F}} = 323.6$ Hz), 115.4, 114.0, 110.6, 63.1, 55.3, 53.2, 26.4; IR (KBr) ν 2945, 2159, 1604, 1491, 1389, 1274, 1225, 1187, 1156, 1062, 1002, 881, 770 cm^{-1} ; HRMS (EI) calcd for $\text{C}_{12}\text{H}_{11}\text{F}_3\text{N}_2\text{O}_3\text{S} [\text{M}]^+$ 320.0442, found 320.0447.

1-(4-Methoxy-2-(trifluoromethylsulfonyl)isoindolin-1-yl)propan-2-one (4i)




^1H NMR (700 MHz, CDCl_3) δ 7.25 (t, $J = 7.9$ Hz, 1H), 6.78 (t, $J = 8.6$ Hz, 2H), 5.60 (br s, 1H), 4.85 (d, $J = 13.7$ Hz, 1H), 4.74 (d, $J = 13.7$ Hz, 1H), 3.82 (s, 3H), 3.23 (dd, $J = 17.8, 2.0$ Hz, 1H), 3.03 (dd, $J = 17.9, 8.1$ Hz, 1H), 2.11 (s, 3H); ^{13}C NMR (175 MHz, CDCl_3) δ 204.6, 154.4, 140.5, 130.2, 122.7, 120.2 (q, $J_{\text{C}-\text{F}} = 324.2$ Hz), 114.5, 109.5, 63.0, 55.3, 52.7, 50.1, 30.6; IR (KBr) ν 2919, 2065, 1713, 1681, 1600, 1490, 1385, 1270, 1225, 1182, 1063, 1027, 883, 778 cm^{-1} ; HRMS (EI) calcd for $\text{C}_{13}\text{H}_{14}\text{F}_3\text{NO}_4\text{S} [\text{M}]^+$ 337.0596, found 337.0602.

1,1,1-Trifluoro-N-(2-methoxy-6-(3-oxobutyl)benzyl)methanesulfonamide (4ii)




¹H NMR (700 MHz, CDCl₃) δ 7.22 (t, *J* = 8.0 Hz, 1H), 6.78 (d, *J* = 7.7 Hz, 1H), 6.75 (d, *J* = 8.1 Hz, 1H), 6.16 (br s, 1H), 4.50 (d, *J* = 5.6 Hz, 2H), 3.84 (s, 3H), 2.91 (t, *J* = 7.2 Hz, 2H), 2.80 (t, *J* = 7.1 Hz, 2H), 2.11 (s, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 208.1, 157.9, 140.9, 129.7, 121.9, 121.6, 119.7 (q, *J*_{C-F} = 321.8 Hz), 108.5, 55.6, 44.3, 39.8, 30.0, 25.7; IR (KBr) ν 2924, 1991, 1707, 1679, 1587, 1440, 1368, 1269, 1226, 1184, 1143, 1091, 1040, 996, 883, 783 cm⁻¹; HRMS (EI) calcd for C₁₃H₁₆F₃NO₄S [M]⁺ 339.0752, found 339.0751.

2-(4-Methoxy-2-(trifluoromethylsulfonyl)isoindolin-1-yl)-1-phenylethanone (4j)




¹H NMR (400 MHz, CDCl₃) δ 7.90 (d, *J* = 7.2 Hz, 2H), 7.55 (t, *J* = 7.4 Hz, 1H), 7.43 (t, *J* = 7.8 Hz, 2H), 7.22 (t, *J* = 8.0 Hz, 1H), 6.83 (d, *J* = 7.7 Hz, 1H), 6.76 (d, *J* = 8.2 Hz, 1H), 5.86 (br s, 1H), 4.91 (d, *J* = 13.9 Hz, 1H), 4.81 (d, *J* = 13.9 Hz, 1H), 3.82 (s, 3H), 3.78 (dd, *J* = 17.8, 2.6 Hz, 1H), 3.58 (dd, *J* = 17.6, 8.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 196.2, 154.3, 140.6, 136.4, 133.5, 130.1, 128.7, 128.0, 122.7, 115.0, 109.5, 63.5, 55.3, 52.7, 30.9; IR (KBr) ν 2940, 2160, 1683, 1599, 1491, 1385, 1271, 1225, 1183, 1146, 1062, 982, 755 cm⁻¹; HRMS (EI) calcd for C₁₈H₁₆F₃NO₄S [M]⁺ 399.0752, found 399.0751.

1,1,1-Trifluoro-N-(2-methoxy-6-(3-oxo-3-phenylpropyl)benzyl)methanesulfonamide (4jj)




¹H NMR (700 MHz, CDCl₃) δ 7.96 (dd, *J* = 8.4, 1.1 Hz, 2H), 7.58 (t, *J* = 7.3 Hz, 1H), 7.46 (t, *J* = 8.1 Hz, 1H), 7.27 (t, *J* = 8.0 Hz, 1H), 6.89 (d, *J* = 7.7 Hz, 1H), 6.80 (d, *J* = 8.0 Hz, 1H), 6.38 (br s, 1H), 4.62 (d, *J* = 5.6 Hz, 2H), 3.89 (s, 3H), 3.40 (t, *J* = 7.1 Hz, 2H), 3.16 (t, *J* = 7.0 Hz, 2H); ¹³C NMR (175 MHz, CDCl₃) δ 199.1, 158.0, 141.1, 136.5, 133.3, 129.7, 128.6, 128.1, 122.5, 122.0, 121.7, 120.7 (q, *J*_{C-F} = 319.7 Hz), 117.9, 108.5, 55.6, 39.9, 39.5, 26.0; IR (KBr) ν 2943, 2159, 1679, 1586, 1418, 1369, 1266, 1226, 1284, 1142, 1090, 1041, 974, 735 cm⁻¹; HRMS (EI) calcd for C₁₈H₁₈F₃NO₄S [M]⁺ 401.0909, found 401.0906.

Chemoselectivity between triflamide **1a** and α,β -unsaturated ketones **2i** and **2j** depending on solvents




solvent	yield (%) of 4i	yield (%) of 4ii
DMF/AcOH (3:1)	4	20
MeCN	54	16
MeCN/AcOH (3:1)	5	7




solvent	yield (%) of 4j	yield (%) of 4jj
DMF/AcOH (3:1)	16	55
MeCN	52	16

Competition experiments




Butyl 2-(4-methoxy-3-oxo-1,3-dihydroisobenzofuran-1-yl)acetate (**5b**)



¹H NMR (700 MHz, CDCl₃) δ 7.58 (t, *J* = 7.6 Hz, 1H), 6.97 (d, *J* = 7.5 Hz, 1H), 6.91 (d, *J* = 8.3 Hz, 1H), 5.75 (t, *J* = 6.8 Hz, 1H), 4.12 (t, *J* = 6.7 Hz, 2H), 3.96 (s, 3H), 2.83–2.81 (m, 2H), 1.59–1.57 (m, 2H), 1.35–1.31 (m, 2H), 0.89 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 169.3, 167.8, 158.6, 151.5, 136.5, 113.5, 113.3, 111.1, 75.9, 65.1, 56.0, 39.6, 30.5, 19.0, 13.6; IR (KBr) ν 2960, 2160, 1760, 1730, 1602, 1486, 1315, 1276, 1198, 1170, 1036, 1008, 965, 777 cm⁻¹; HRMS (EI) calcd for C₁₅H₁₈O₅ [M]⁺ 278.1154, found 278.1160.


Dibutyl 2,2'-(3-oxo-6-(trifluoromethylsulfonyl)-3,5,6,7-tetrahydro-1H-furo[3,4-f]isoindole-1,5-diyl)diacetate (**6b**)



¹H NMR (700 MHz, CDCl₃) δ 7.77 (s, 1H), 7.42 (s, 1H), 5.86 (t, *J* = 6.5 Hz, 1H), 5.61 (br s, 1H), 5.02–4.92 (m, 2H), 4.16 (t, *J* = 6.7 Hz, 2H), 4.05–3.99 (m, 2H), 3.13 (dd, *J* = 17.3, 6.3


Hz, 1H), 3.08–3.00 (m, 2H), 2.85 (dd, $J = 16.7, 6.9$ Hz, 1H), 1.64–1.60 (m, 2H), 1.55–1.52 (m, 2H), 1.39–1.35 (m, 2H), 1.31–1.26 (m, 2H), 0.94 (t, $J = 7.4$ Hz, 3H), 0.89 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (175 MHz, CDCl_3) δ 169.3, 169.2, 168.7, 149.8, 142.6, 140.5, 126.8, 120.1, 116.8, 76.7, 65.3, 65.0, 62.4, 54.4, 39.3, 30.9, 30.5, 19.0, 18.9, 13.7, 13.6; IR (KBr) ν 2961, 2159, 1766, 1729, 1631, 1459, 1389, 1304, 1224, 1179, 1117, 1064, 1006, 789 cm^{-1} ; HRMS (EI) calcd for $\text{C}_{23}\text{H}_{28}\text{F}_3\text{NO}_8\text{S} [\text{M}]^+$ 535.1488, found 535.1481.

(E)-Butyl 3-(1-(2-butoxy-2-oxoethyl)-3-oxo-6-((trifluoromethylsulfonamido)methyl)-1,3-dihydroisobenzofuran-5-yl)acrylate (6c)



^1H NMR (700 MHz, CDCl_3) δ 8.33 (d, $J = 16.0$ Hz, 1H), 7.64 (s, 1H), 7.49 (s, 1H), 6.84 (br s, 1H), 6.44 (d, $J = 16.0$ Hz, 1H), 5.71 (t, $J = 6.4$ Hz, 1H), 4.56 (s, 2H), 4.17 (t, $J = 6.3$ Hz, 2H), 4.09 (t, $J = 6.7$ Hz, 2H), 2.88 (t, $J = 6.1$ Hz, 2H), 1.68–1.64 (m, 2H), 1.59–1.55 (m, 2H), 1.42–1.38 (m, 2H), 1.34–1.31 (m, 2H), 0.93 (t, $J = 7.4$ Hz, 3H), 0.90 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (175 MHz, CDCl_3) δ 169.3, 168.6, 166.6, 150.7, 143.4, 136.9, 135.0, 125.9, 123.1, 122.9, 122.4, 119.7 (q, $J_{\text{C}-\text{F}} = 318.9$ Hz), 76.2, 65.4, 65.2, 47.4, 38.8, 30.5, 30.4, 19.1, 19.0, 13.6, 13.5 ; IR (KBr) ν 2962, 2160, 2018, 1761, 1732, 1641, 1602, 1459, 1376, 1229, 1183, 1147, 1059, 1016, 871, 734 cm^{-1} ; HRMS (EI) Calcd for $\text{C}_{23}\text{H}_{28}\text{F}_3\text{NO}_8\text{S} [\text{M}]^+$ 535.1488, found 535.1486.

General procedure for deprotection of triflamide group




To a stirred solution of **3a** (150.0 mg, 0.38 mmol, 1.0 equiv.) in diethyl ether (4 mL) was added LiAlH₄ (57.5 mg, 1.52 mmol, 4.0 equiv.) at 0 °C. The reaction mixture was stirred for 12 h at 50°C. After cooling to room temperature, the reaction mixture was quenched with water and the aqueous layer was extracted with diethyl ether (10 mL × 3). The combined organic layer was dried over Mg₂SO₄ and concentrated in vacuo. The residue was purified by C₁₈ reversed-phase silica gel column chromatography (MeOH:H₂O:Et₃N = 90:10:0.2) to afford free (NH)-isoindoline **7a** (53.1 mg) in 72% yield.

2-(4-Methoxyisoindolin-1-yl)ethanol (**7a**)



¹H NMR (500 MHz, CDCl₃) δ 7.26 (t, *J* = 8.0 Hz, 1H), 6.77 (d, *J* = 7.5 Hz, 1H), 6.73 (d, *J* = 8.0 Hz, 1H), 4.70 (br s, 1H), 4.19 (s, 2H), 3.86–3.76 (m, 7H), 2.02–1.96 (m, 1H), 1.84–1.78 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 155.2, 145.9, 129.2, 129.0, 114.5, 108.9, 64.9, 62.0, 55.4, 49.0, 35.9; IR (KBr) ν 3331, 3301, 2926, 2853, 1596, 1546, 1485, 1440, 1267, 1184, 1062, 773 cm⁻¹; LC/MS (ESI) [M+H]⁺ 194.29.





General Procedure of Mechanistic Studies











To an oven-dried sealed tube charged with *N*-(2-methoxybenzyl)triflamide (**1a**) (80.8 mg, 0.3 mmol, 100 mol %), $[\text{RhCp}^*\text{Cl}_2]_2$ (4.6 mg, 0.0075 mmol, 2.5 mol %), and $\text{Cu}(\text{OAc})_2$ (108 mg, 0.6 mmol, 200 mol %) in DMF:AcOD (3:1, 1 mL) was allowed to stir for 17 h at $110\text{ }^\circ\text{C}$. The reaction mixture was diluted with EtOAc (10 mL) and washed with water. The aqueous layer was extracted with EtOAc (3×10 mL). The combined organic layer was dried over Mg_2SO_4 and concentrated in vacuo. The residue was purified by flash column chromatography (*n*-hexanes/EtOAc = 25:1) to afford **1a/deutrio-1a** in 92% yield.






















































SpinWorks 3: JH1059















SpinWorks 3: NK14















































SpinWorks 3: NK49-1





SpinWorks 3: NK49-1









SpinWorks 3: NK40

